December 17, 2012Date Released: 17 December 2012
CASE CCC IN THE NEWS
Vitamin D cuts breast cancer death risk in overweight and obese
ANNOUNCEMENTSDr. Neal Meropol Appointed to American Society of Clinical Oncology Board of Directors
The American Society of Clinical Oncology (ASCO) today announced the appointment of Neal J. Meropol, MD, to its 18-member Board of Directors. ASCO is the world's leading professional organization representing physicians who care for people with cancer.
The ASCO Board of Directors is responsible for executing the mission, vision and strategic management of the organization and translating ASCO's mission into ongoing programs that attain the organization's goals. With more than 30,000 members, ASCO is committed to improving cancer care through scientific meetings, educational programs and peer-reviewed journals. [more]
Dr. David Wald Honored with Ohio Cancer Research Associates Award
Dr. David Wald was recently honored with the "Seed Money Award" from the Ohio Cancer Research Associates (OCRA) for his work in leukemia drug development. A $60,000, two-year seed-money grant from OCRA enabled Dr. Wald and his research team to secure an additional $2.62 million in national funding–$1.9 million from the National Institutes of Health and $720,000 from the American Cancer Society–for his cancer drug development research.
Dr. Sanford Markowitz Recognized as a Top-Physician Scientist by Harrington Scholar-Innovator Grant
Dr. Sanford Markowitz was one of only ten recipients nation-wide of the inaugural Harrington Scholar-Innovator grants, given out by the Harrington Discovery Institute at UH Case Medical Center. This program is focused on supporting the nation's best physician-scientists and their efforts to accelerate promising drug discoveries into novel treatments for patients.
A competitive grant competition was held in May to identify the nation's most promising medical breakthroughs and to accelerate their entry into the clinic. Dr. Markowitz was selected for his research on Pulmonary HTN & Liver Regeneration: Discovery of a novel compound that increases tissue prostaglandins to treat multiple human diseases, including pulmonary hypertension, liver regeneration and cancer.Obtaining Human Tissues for Cancer Research
The Case CCC wishes to make its members aware that a Data Use Agreement has been approved by the University Hospitals Legal Affairs Office. This Data Use Agreement will greatly facilitate obtaining tissue for cancer research in situations where protected health information is not necessary for the research.
A wide variety of tissues is available from the Tissue Resources Core, and samples from the hospital's clinical archives of paraffin-embedded tissues may also be obtained. You are encouraged to visit the Tissue Resources website for information about available biospecimens. Application forms are accessible from the Case CCC Tissue Resources page, and from the Clinical Research Office page.
Use the Tissue Research Application for studies that involve research activities limited to archived or discarded tissue. Contact David Goldblatt at 216.844.5060,email@example.com and/or Kristin Waite at 216.844.5537, firstname.lastname@example.org for guidance on the application process.
FUNDING OPPORTUNITIES/AWARDSLimited Submission: Mary Kay Foundation
The Mary Kay Foundation is currently accepting applications for innovative grants for translational research in ovarian, uterine, breast, or cervical cancer. The Case CCC may submit ONE grant application. Interested candidates should forward the project abstract and their biosketch to Kristin Waite by January 4, 2013.
Internal Deadline: January 4, 2013
The Samuel Waxman Cancer Research Foundation (SWCRF)seeks to develop scientific programs in the form of an Institute Without Walls. These programs span multiple institutions and disciplines and identify the optimal set of investigators to unravel and reverse the abnormal program of growth and differentiation of the cancer cell. The Foundation envisions that members of the SWCRF Institute Without Walls will continue interactions beyond the term of their grant. The focus of this RFA is the identification of targets, novel compounds, and potential therapies that can reprogram abnormal cancer gene function. Specific themes of interest to the SWCRF include studies that address aberrant gene regulation, transcriptional and signal transduction, epimutations, and cell dormancy vs. proliferation.
The Case CCC has been invited to submit ONE application for this opportunity. Interested candidates should forward the project abstract and their biosketch to Kristin Waite.
Internal Deadline: January 25, 2013
The National Research Council of the National Academies is pleased to announce the Graduate, Postdoctoral and Senior Research Associateship Programs for 2013. These programs provide opportunities for PhD, ScD, or MD scientists and engineers of unusual promise and ability to perform research on problems largely of their won choosing, yet compatible with the research interests of the sponsoring laboratory.
Application deadlines are February 1, May 1, August 1 and November 1.Prostate Cancer Foundation 2013 Young Investigator Awards
The Prostate Cancer Foundation (PCF) is accepting applications for the 2013 Young Investigator Awards. Highly innovative basic science programs will be carefully considered, but priority will be given to "bench to bedside" translational research proposals with the potential to deliver near term benefit to patients. PCF welcomes applications from the global community. Applicants need not be trained specifically in clinical prostate cancer research. Young Investigators may be working in basic, translational, clinical, population sciences, bioengineering or any other field that could contribute to the end of prostate cancer. However, successful applicants should be working in a research environment capable of supporting transformational prostate cancer research. Access to and interaction with a clinical environment, as well as translational prostate cancer physician-scientists, is highly desirable. Research molecular pathologists and bioinformaticians are especially encouraged to apply for this award.
Deadline: February 1, 2013Leukemia and Lymphoma Society Translational Research Program
The Leukemia and Lymphoma Society (LLS) has released an RFP for its Translational Research Program (TRP). This program was developed to encourage and provide early-stage support for clinical research in leukemia, lymphoma and myeloma, which is intended to develop innovative approaches to treatment, diagnosis or prevention. Proposals should be based on molecular, cellular or integrated systems findings and be conceptually innovative. The application should have a clear plan for the clinical exploitation of the studies proposed and the results expected. This feature of the proposal will be an important consideration of the review process. While work directed at a further elucidation and understanding of the fundamental cellular and molecular biology of neoplastic lymphohematopoietic cells is a research priority of LLS, the TRP is specifically intended for the support of work which is clearly clinical in orientation with an overall goal to result in a clinical trial and/or TRP renewal.
LOI Deadline: March 1, 2013
MARK YOUR CALENDARSMonthly Cancer Trainee Seminar Series
The Cancer Trainee Seminar Series is a monthly seminar open to anyone working on a cancer-related project, though it is focused on cancer biology trainees. In this series, a trainee will give a 30-minute talk on their work, followed by a 20-minute talk by a clinician who may present on the same disease as the trainee, but from a clinical point of view.<.
This seminar series serves multiple purposes. First, it provides trainees with a cancer-centric audience of their peers and faculty members, to allow them to receive critical feedback on their presentation skills. Second, the series exposes trainees to the clinical management of cancer. This component of the series was included because there was a general consensus among trainees that they wanted more clinical exposure to cancer in order to enable them to extend their basic research findings into the translational research arena. Finally, the series can facilitate collaborative interaction among trainees from different departments, where interactions may be less likely.
These meetings will be held the third Thursday of each month at 12 pm in Wolstein Research Building 3-136. Lunch will be provided. If you have a trainee you think might benefit from this series, please send their e-mail address to Kristin Waite (email@example.com), so they can be added to the mailing list.
Cancer Center Research Chalk Talk
Stem Cell Biology and Regenerative Medicine Seminar Mid-Term Review
Pathology Research Seminar Series
Sequencing Data Interest Group
Skeletal Research Center Seminar
Molecular Genetics Departmental Seminar Series
Immunology Seminar Series
Hematology and Oncology Division Research Conference
Genetics and Genome Sciences Seminar
Immunology Faculty Research in Progress Series
20th Annual Robert R. Kohn Lecture
Stem Cell Biology and Regenerative Medicine Seminar
Cancer Center Seminar
Hematology/Oncology Fellows Conference/Curriculum Series
Taussig Cancer Institute Grand Rounds
Cancer Center Seminar Series
Cancer Center Research in Progress
Case CCC Calendar
UPCOMING CANCER CENTER SYMPOSIUMS & EVENTS
16th Annual Meeting of the Translational Research Cancer Centers Consortium (TRC3): The Power of Negative Thinking: Inhibiting the Inhibitors of Tumor Immunity
ADDITIONAL UPCOMING SEMINARS & EVENTS
American Society of Hematology (ASH) Annual Meeting
So You Want To Do Comparative Effectiveness Research? The Nuts and Bolts of CER
Pacific Symposium on Biocomputing 2013
PREVIOUSLY ANNOUNCED OPPORTUNITIES
CTSC Explorys Collaborative Pilots
Oncology Nursing Society Foundation Doctoral Degree Scholarships
NIH BULLETIN – Notices and Funding Opportunities
Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01)(PAR-13-036)
HELP US HELP YOU!
If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades!
Send items to firstname.lastname@example.org.